Abstract
Phototherapy is the standard treatment in moderately severe hemolytic disease of newborn (HDN), whereas exchange transfusion (ET) is the second line in progressive cases. Intravenous immunoglobin (IVIG) has been suggested to decrease the need for ET. We aimed at assessing the efficacy of early two-dose regimens of IVIG to avoid unnecessary ET in severe Rh HDN. The study included 90 full-term neonates with Rh incompatibility unmodified by antenatal treatment and not eligible for early ET and which were randomly assigned into one of three groups: group (I), treated by conventional method; groups IIa and IIb received IVIG once at 12 h postnatal age if PT was indicated, in a dose of 0.5 and 1 g/kg, respectively. Analysis revealed 11 neonates (22%) in the conventional group and 2 (5%) in the intervention group who administered low-dose IVIG at 12 h, while none in group IIb required exchange transfusion (p = 0.03). Mean bilirubin levels were significantly lower during the first 96 h in the intervention group compared to the conventional group (p < 0.0001). Shorter duration of phototherapy (52.8 ± 12.39 h) and hospital stay (3.25 ± 0.71 days) in the IVIG group compared to conventional group (84 ± 12.12 h and 4.72 ±0.78 days, p < 0.0001, respectively) were observed. We conclude that IVIG administration at 12 h was effective in the treatment of severe Rh HDN; the low-dose IVIG (0.5 g/kg) was as effective as high dose (1 g/kg) in reducing the duration of phototherapy and hospital stay, but less effective in avoiding exchange transfusion.
Similar content being viewed by others
References
Alpay F, Sarici SU, Okutan V, Erdem G, Ozcan O, Gokcay E (1999) High dose intravenous immunoglobulin therapy in neonatal immune hemolytic jaundice. Acta Paediatr 88(2):216–219
American Academy of Pediatrics (2004) Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation (Subcommittee on Hyper-bilirubinemia). Pediatrics 114(1):297–316
Behjati Sh, Sagheb S, Aryasepehr S, Yaghmai B (2009) Adverse events associated with neonatal exchange transfusion for hyperbilirubinemia. Indian J Pediatr 76(1):83–85
Colletti JE, Kothari S, Jackson DM, Kilgore KP, Barringer K (2007) An emergency medicine approach to neonatal hyperbilirubinemia. Emerg Med Clin North Am 25(4):1117–1135, vii
Cooper N (2009) Intravenous immunoglobulin and anti-Rh D therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am 23(6):1317–1327
Cortey A, Brossard Y (2006) Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects. J Gynecol Obstet Biol Repord (Paris) 35(1 suppl):1S123–1S130
Demirel N, Aydin M, Zenciroglu A, Bas AY, Yarali N, Okumus N, Cinar G, Ipek MS (2009) Neonatal thrombo-embolism: risk factors, clinical features and outcome. Ann Trop Paediatr Dec 29(4):271–279
Figueras-Aloy J, Rodriguez-Miguelez JM, Iriondo-Sanz M et al (2010) Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics 125(1):139–144
Girish G, Chawla D, Agarwal R, Paul VK, Deorari Ak (2008) Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemolytic disease of newborn—a randomized controlled trial. Indian Pediatr 45(8):653–659
Gobalakichenane P, Lardennois C, Galène-Gromez S et al (2008) Perinatal management and neurological outcome of newborns hospitalized with rhesus hemolytic disease. Gynécol Obstét Fertil 36(10):984–990
Gordon S (2001) Mononuclear phagocytes in immune defense. In: Roitt I, Brostoff J, Male D (eds) Immunology, 6th edn. Mosby, St. Louis, pp 155–156
Gottstein R, Cooke RW (2003) Systemic review of intravenous immunoglobulin in hemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 88(1):F6–F10
Greenough A (1999) Rhesus disease: postnatal management and outcome. Eur J Pediatr 158(9):689–693
Hammerman C, Kaplan M (2000) Recent developments in the management of neonatal hyperbilirubinemia. NeoReviews 1:19–24
Huizing K, Røislien J, Hansen T (2008) Intravenous immune globulin reduces the need for exchange transfusions in rhesus and AB0 incompatibility. Acta Paediatr 97(10):1362–1365
Kirk JM (2008) Neonatal jaundice: a critical review of the role and practice of bilirubin analysis. Ann Clin Biochem 45(pt5):452–462
Kriplani A, Malhotra Singh B, Mandal K (2007) Fetal intravenous immunoglobulin therapy in rhesus hemolytic disease. Gynecol Obstet Invest 63(3):176–180
Maisels MJ, McDonagh Ak (2008) Phototherapy for neonatal jaundice. N Engl J Med 358(9):920–928
Malhotra A, Carse E (2009) Survey of management of neonatal haemolytic jaundice in Australasia. J Paediatr Child Health 46(5):222–225
Miqdad AM, Abdelbasit OB, Shaheed MM, Seidahmed Mz, Abomella AM, Arcala OP (2004) Intravenous immunoglobulin therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. J Matern Fetal Neonatal Med 6(3):163–166
Moise KJ (2008) Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 112(1):164–176
Monpoux F, Dageville C, Maillotte AM, De Smet S, Casagrande F, Boutté P (2009) High-dose intravenous immunoglobulin therapy and neonatal jaundice due to red blood cell alloimmunization. Arch Pediatr 16(9):1289–1294
Mukhopadhyay K, Murki S, Narang A, Dutta S (2003) Intravenous immunoglobulin in rhesus hemolytic disease. Indian J Pediatr 70(9):697–699
Mundy CA (2005) Intravenous immunoglobulin in the management of hemolytic disease of the newborn. Neonatal Netw 24(6):17–24
Murray NA, Roberts IA (2007) Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 92(2):F83–F88
Navarro M, Negre S, Golombek S, Matoses ML, Vento M (2010) Intravenous immune globulin: clinical applications in the newborn. NeoReviews 11(7):e370–e378
Oepkes D, Adama van Scheltema P (2007) Intrauterine fetal transfusions in the management of fetal anemia and fetal thrombocytopenia. Semin Fetal Neonatal Med 12(6):432–438
Roberts IA (2008) The changing face of haemolytic disease of the newborn. Early Hum Dev 84(8):515–523
Smits S, Wintjens VE, Walther FJ, Lopriore E (2008) Rhesus hemolytic disease of the newborn: postnatal management, associated morbidity and long term outcome. Semin Fetal Neonatal Med 13(4):265–271
Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG (2007) A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics 120(1):27–32
Tanyer G, Siklar Z, Dallar Y, Yildirmak Y, Tiras V (2001) Multiple dose intravenous immunoglobulin treatment in neonatal immune hemolytic jaundice. J Trop Pediatr 47(1):50–53
Voto L, Sexer H, Ferreiro G, Tavosnanska J, Orti J, Mathet ER, Margulies M (1995) Neonatal administration of high dose intravenous immunoglobulin in rhesus hemolytic disease. J Perinat Med 23(6):443–451
Conflict of interests
The authors declare that they have no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Elalfy, M.S., Elbarbary, N.S. & Abaza, H.W. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn—a prospective randomized controlled trial. Eur J Pediatr 170, 461–467 (2011). https://doi.org/10.1007/s00431-010-1310-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-010-1310-8